Quest Diagnostics

Quest Diagnostics Incorporated (NYSE: DGX) is the world’s leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its industry-leading medical and scientific staff of approximately 900 M.D.s and Ph.D.s. The company reported 2008 revenues of $7.2 billion, has approximately 43,000 employees and serves approximately half of all physicians and hospitals in the United States.

Quest Diagnostics offers the most extensive clinical testing network in the United States, operating laboratories in most major metropolitan areas, and in Mexico, the United Kingdom and India. These laboratories perform routine clinical tests that help physicians know when a patient is within or outside normal limits for a clinical condition. The company is the leader in cancer diagnostics and provides anatomic pathology services, including inpatient anatomic pathology and medical director services, at hospitals throughout the country.

Quest Diagnostics is the leading provider in the United States of gene-based and other esoteric testing. At its four esoteric testing laboratories, highly skilled technical personnel use sophisticated technology, equipment or materials to gain such patient insights as a patient’s response to treatment; changes taking place in the body in the early stages of disease when treatment may be most effective; or inherited genetic characteristics that may indicate an elevated risk to a patient—or the patient’s offspring—of a susceptibility to a disease. The company’s world-renowned Nichols Institute, with locations in San Juan Capistrano, California, and Chantilly, Virginia, specializes in esoteric testing, including genetic testing, and conducts research and development.

Patients may have their specimens collected in any of the company’s approximately 2,000 conveniently located patient service centers. On a typical workday, the company performs testing for approximately 550,000 patients. Quest Diagnostics laboratories operate 24 hours a day, 365 days a year, touching the lives of patients more than 150 million times each year. The company has strong logistics capabilities, including approximately 3,500 courier vehicles and 25 aircraft that make approximately 90,000 stops daily to pick up and deliver patient specimens.

Quest Diagnostics offers physicians the broadest test menu of any diagnostics company, with more than 3,000 tests, and is a pioneer in developing innovative new diagnostic tests as well as advanced healthcare information technology solutions that can help improve patient care. Through its MedPlus subsidiary, Quest Diagnostics empowers healthcare organizations and clinicians with state-of-the-art connectivity solutions that help improve patient care and practice management. Its Care360™ suite of connectivity products currently supports and networks more than 150,000 U.S. physicians. In 2008, physicians ordered 4.5 million drug prescriptions on an annualized basis using Care360.

Quest Diagnostics is the leading provider of both pre-employment drugs-of-abuse screening for employers, and risk assessment services for the life insurance industry. The company publishes the Drug Testing Index (DTI), an aggregation of more than seven million employer drug testing results annually that has long been considered a benchmark for U.S. workforce drug positivity trends since its inception in 1988. The company is the world’s second largest provider of clinical trials testing for new pharmaceuticals.

2009 Facts at a Glance

• Quest Diagnostics Incorporated (NYSE: DGX) is the world’s leading provider of diagnostic testing, information and services with 2008 revenues of approximately $7.2 billion.
• The leading cancer diagnostic testing provider.
• 900 MDs and PhDs.
• Workforce of 43,000 employees dedicated to putting patients first every day.
• Serves half of all physicians and hospitals in the U.S.
• Supports and networks more than 150,000 physicians who use its Care360 suite of connectivity products to order lab tests, view results, share clinical information. Using Care360, physicians have ordered 4.5 million electronic drug prescriptions on an annualized basis.
• More than 2,000 patient service centers.
• Offers physicians the broadest test menu, with more than 3,000 tests, regularly pioneering new advancements in diagnostics testing that help improve patient care.
• Most extensive clinical testing network with laboratory presence in most U.S. major metropolitan areas, as well as Mexico, the United Kingdom and India, and four esoteric testing laboratories (including the world-renowned Quest Diagnostics Nichols Institute in Chantilly, VA and San Juan Capistrano, CA).
• Anatomic pathology services, including in-patient anatomic pathology and medical director services at hospitals.
• Leading provider of esoteric testing services, including gene-based testing; esoteric and gene-based tests generated $1.4 billion in revenues in 2008.
• Strong logistics capabilities, including approximately 3,500 courier vehicles and 25 airplanes that make approximately 90,000 stops daily.
• Manufactures point-of-care testing instruments and test kits in Sweden and Australia, with distribution in more than 130 countries.
• Leading provider of risk assessment services to the life insurance industry.
• Leading provider of workplace drug testing, publishing the Quest Diagnostics Drug Testing Index (DTI), long considered a benchmark for U.S. workforce drug positivity trends since its inception in 1988.